Pay in 4 interest-free payments of $6.09 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
AOD9604 caused only a modest weight increase, which was statistically significant only on the last day of the 14-day treatment period
Clinical Evidence: The STEP Program The STEP clinical trial program is the most relevant evidence base for semaglutide's weight management indication
Your physician can perform a cardiac electrocardiogram (EKG) if needed to check the health of your body
They carefully assess each patients unique needs, health history, and goals before initiating therapy, ensuring a tailored experience that prioritizes both safety and effectiveness
Potential Metabolic Rate Enhancement: Through activation of beta-3 adrenergic receptors and thermogenic effects, AOD-9604 may increase resting energy expenditure
US$ 27.03
US$ 24.05
US$ 28.69
